Biognosys welcomes Dr. Beat Lüthi to its Board as Independent Director

– SWITZERLAND, Zurich –  Biognosys, a leader in next-generation proteomics solutions for life science research and drug development, today announced the appointment of Dr. Beat Lüthi (Ph.D.) to its Board as Independent Director.

“I am delighted to welcome Dr. Lüthi as Board Director to support our next growth stage with his extensive experience as life sciences executive and board director. I would also like to thank our prior Board Director, Winfried Mayer, for his many years of invaluable service to our board,” said CEO, Dr. Oliver Rinner.

About Dr. Beat Lüthi

Dr. Lüthi is CEO of CTC Analytics AG, a privately owned Swiss company leading in automation and advanced laboratory sample handling solutions for the pharmaceutical, life science, chemical, environmental, and food & flavor industries. Additionally, he holds several Board of Directors mandates in public firms, including Chairman of Inficon Group, Vice-Chairman of Straumann Group, and Board Member of Skan AG.

Dr. Lüthi holds an M.Sc. in Electrical Engineering and a Ph.D. in Business Administration from ETH Zurich and completed an International Executive Program at the INSEAD Business School.

As Board Director at Biognosys, Dr. Lüthi will be instrumental in the company’s transformation to a leading provider and partner for protein insights to drive the development of breakthrough treatments.

“I am excited to join Biognosys at a time when proteomics is widely adopted to accelerate life science research and development,” said Dr. Lüthi. “The company is at an inflection point of strengthening its global leadership position in the proteomics field and I am looking forward to being part of this journey.”

About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including TrueDiscovery, TrueTarget, and TrueSignature platforms and flagship software Spectronaut. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research.

For more information: https://biognosys.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.